Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Synergistic induction of monocyte chemoattractant protein-1 (MCP-1) by platelet-derived growth factor and interleukin-1.

Authors: Goppelt-Struebe, M  Stroebel, M 
Citation: Goppelt-Struebe M and Stroebel M, FEBS Lett. 1995 Nov 6;374(3):375-8.
Pubmed: (View Article at PubMed) PMID:7589574

Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the recruitment of monocytic cells to the site of inflammation. Resting mesangial cells express barely detectable levels of MCP-1 mRNA. Treatment of rat mesangial cells with platelet products PDGF-AB, PDGF-BB or serotonin transiently induced MCP-1 expression with a maximum after 2 to 4 h and a decline to baseline after 6 to 8 h. Different kinetics were observed with interleukin-1 beta (IL-1 beta), which induced a long lasting elevation of MCP-1 mRNA for more than 20 h. Together, PDGF and IL-1 beta synergistically induced MCP-1 expression. The effect was most obvious after 16 to 20 h, when induction by PDGF alone had already faded, but still PDGF strongly enhanced IL-1 beta-induced MCP-1 mRNA expression. MCP-1 mRNA levels were regulated by changes in the stability of the mRNA: inhibition of protein synthesis by cycloheximide by itself induced MCP-1 mRNA expression and led to superinduction in the presence of PDGF. Message stabilization also contributed to the synergistic action of PDGF and IL-1 beta: the apparent half life of MCP-1 mRNA determined in the presence of actinomycin D was prolonged when both stimuli were added together. We could thus show that in mesangial cells different types of cytokines and growth factors synergize to enhance MCP-1, the secretion of which could lead to the recruitment of monocytic cells into the inflamed mesangium.

Annotation

Gene Ontology Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 8549588
Created: 2014-03-31
Species: All species
Last Modified: 2014-03-31
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.